Low-dose oral propranolol could reduce brown adipose tissue F-18FDG uptake in patients undergoing PET scans
Low-dose oral propranolol could reduce brown adipose tissue F-18FDG uptake in patients undergoing PET scans
复制标题
DOI：
10.1097/01.rlu.0000259570.69163.04
复制
发表时间：
2007-05-01
影响因子：
10.6
通讯作者：
Gerbaudo, Victor H.
中科院分区：
文献类型：
--
作者：
Parysow, Oscar;Mollerach, Ana M.;Gerbaudo, Victor H.
褐色脂肪组织（BAT）对氟-18氟-2-脱氧-d -葡萄糖（FDG）的摄取可能会产生FDG- pet扫描的误解。最近的研究表明，大鼠服用高剂量的β受体阻滞剂心得安后，BAT中FDG的摄取减少。本观察性研究的目的是介绍一组接受低剂量普萘洛尔后接受第二次扫描的BAT中FDG摄取高的患者，以确定使用这种预用药是否可以通过抑制BAT中FDG摄取来提高FDG- pet扫描的诊断信度，以及该药物的给药是否影响肿瘤中示踪剂的摄取。方法：前瞻性选择26例出现BAT FDG摄取增高的肿瘤患者。在另一天，患者在FDG给药前61分钟口服心得安20 mg (185-277.5 MBq (5-7.5 inCi))，并再次扫描。测定了普萘洛尔基础和后的BAT SUVmax，以及肿瘤SUVmax（当存在时）。结果：平均基础BAT SUV （max）为5.52 +/- 2.3。心得安后平均SUVmax为1.39 +/- 0.42 （P < 0.0001）。在11例患者中，心得安后基础平均肿瘤SUVmax为8.07 +/- 6.4,7.88 +/- 5.9 （P= 0.53）。9例患者基底扫描显示纵隔FDG摄取，影响图像解释。在服用心得安后的扫描中没有观察到这一点。未见心得安的不良反应。结论：在该患者队列中，服用心得安后，BAT中FDG摄取显著减少，允许FDG- pet和软件融合FDG- pet与CT图像充分解释，特别是在纵隔区域，而不影响肿瘤示踪剂的摄取。
Fluorine-18 fluoro-2-deoxy-D-glucose (FDG) uptake in brown adipose tissue (BAT) may generate FDG-PET scan misinterpretation. Recent studies have shown reduced FDG uptake in BAT in rats treated with high doses of the beta-blocker propranolol. The aim of this observational study was to present a cohort of patients with high FDG uptake in BAT who underwent a second scan after receiving a low dose of propranolol, to determine whether the use of this premedication could improve the diagnostic confidence of FDG-PET scans by inhibition FDG uptake in BAT, and also whether administration of this drug affects tracer uptake in tumors.Methods: Twenty-six cancer patients, presenting with increased BAT FDG uptake, were selected prospectively. On a different day, patients were given propranolol 20 mg orally 61) minutes prior to FDG administration 185-277.5 MBq (5-7.5 inCi) and were scanned again. Basal and postpropranolol BAT SUVmax, and tumor SUVmax (when present) were measured.Results: Mean basal BAT SUV,(max) was 5.52 +/- 2.3. Mean postpropranolol SUVmax was 1.39 +/- 0.42 (P < 0.0001). In 11 patients, the SUVmax was 8.07 +/- 6.4, and 7.88 +/- 5.9 in basal mean tumor SUVmax postpropranolol scans (P= 0.53). Nine patients showed mediastinal FDG uptake in the basal scan, affecting image interpretation. This was not observed in postpropranolol scans. No adverse effects due to propranolol were encountered.Conclusions: In this patient cohort, there was significant reduction of FDG uptake in BAT following propranolol administration, allowing for adequate interpretation of FDG-PET and software-fused FDG-PET with CT images, particularly in the mediastinal area, without affecting tumor tracer uptake.